Volume 27, Issue 136, June 2023

Intravitreal dexamethasone sustained release implant in refractory diabetic macular edema

Ahmed Mohamed Ahmed Ibrahim^1♦, Mamdouh Mahmoud Kabeel², Boshra Mohamed Ali Elbayoumi³, Amr Aly Mohamed Elshormilisy⁴, Ahmed Samir Montaser⁵

¹Assistant Lecturer of Ophthalmology Department, Faculty of Medicine, Helwan University, Cairo, Egypt
²Professor of Ophthalmology Department, Faculty of Medicine, Tanta University, Tanta, Egypt
³Professor of Ophthalmology Department, Memorial Institute of Ophthalmology, Giza, Egypt
⁴Assistant Professor of Internal Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt
⁵Lecturer of Ophthalmology Department, Faculty of Medicine, Helwan University, Cairo, Egypt

^♦Corresponding author
Assistant Lecturer of Ophthalmology Department, Faculty of Medicine, Helwan University, Cairo, Egypt

ABSTRACT

Purpose: Intravitreal therapies with anti-VEGF medications are regarded as effective treatment option. The biodegradable intravitreal implant, Ozurdex (Allergan, Irvine, CA, USA) depends on slow-release dexamethasone. The present study aimed to assess the effect on best corrected visual acuity and efficacy of intravitreal Ozurdex in patients with refractory DME. Methods: This prospective study included patient with refractory DME who received intravitreal Ozurdex. Baseline clinical evaluation, change in best corrected visual acuity BCVA and central retinal thickness CRT were analysed, intra ocular pressure, adverse effects were recorded. Results: The reported CRT measurements showed significant decrease in the first 3 months post injection, however at 6 months there was a slight increase in CRT. The reported BCV showing significant improvement from the baseline values, there was significant increase in IOP in the first month only which was controlled with medical treatment, no marked side effects were reported in the studied patients. Conclusions: For patients with refractory macular oedema, Ozurdex implant showed improvement in visual acuity and decreased macular thickness. Side effects such as increase of intraocular pressure, may require medical treatment.

Keywords: Dexamethasone, Refractory Diabetic Macular Edema, Macular Edema

Medical Science, 2023, 27, e282ms3038

PDF

DOI: https://doi.org/10.54905/disssi/v27i136/e282ms3038

Published: 29 June 2023